116 related articles for article (PubMed ID: 37724007)
1. Sensitivity of osteosarcoma cell lines to autophagy inhibition as determined by pharmacologic and genetic manipulation.
Gustafson DL; Viola LO; Towers CG; Das S; Duval DL; Van Eaton KM
Vet Comp Oncol; 2023 Dec; 21(4):726-738. PubMed ID: 37724007
[TBL] [Abstract][Full Text] [Related]
2. Lys05: a new lysosomal autophagy inhibitor.
Amaravadi RK; Winkler JD
Autophagy; 2012 Sep; 8(9):1383-4. PubMed ID: 22878685
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency.
McAfee Q; Zhang Z; Samanta A; Levi SM; Ma XH; Piao S; Lynch JP; Uehara T; Sepulveda AR; Davis LE; Winkler JD; Amaravadi RK
Proc Natl Acad Sci U S A; 2012 May; 109(21):8253-8. PubMed ID: 22566612
[TBL] [Abstract][Full Text] [Related]
4. 17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines.
Massimini M; Palmieri C; De Maria R; Romanucci M; Malatesta D; De Martinis M; Maniscalco L; Ciccarelli A; Ginaldi L; Buracco P; Bongiovanni L; Della Salda L
Vet Pathol; 2017 May; 54(3):405-412. PubMed ID: 28438108
[TBL] [Abstract][Full Text] [Related]
5. Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Ong SM; Yamamoto H; Saeki K; Tanaka Y; Yoshitake R; Nishimura R; Nakagawa T
Jpn J Vet Res; 2017 Feb; 65(1):17-28. PubMed ID: 29791117
[TBL] [Abstract][Full Text] [Related]
6. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.
Alegre F; Ormonde AR; Godinez DR; Illendula A; Bushweller JH; Wittenburg LA
Vet Comp Oncol; 2020 Mar; 18(1):52-63. PubMed ID: 31381810
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
8. Research progress of hydroxychloroquine and autophagy inhibitors on cancer.
Shi TT; Yu XX; Yan LJ; Xiao HT
Cancer Chemother Pharmacol; 2017 Feb; 79(2):287-294. PubMed ID: 27889812
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.
Fauzi YR; Nakahata S; Chilmi S; Ichikawa T; Nueangphuet P; Yamaguchi R; Nakamura T; Shimoda K; Morishita K
PLoS One; 2021; 16(8):e0256320. PubMed ID: 34407152
[TBL] [Abstract][Full Text] [Related]
10. Identification of anti-proliferative kinase inhibitors as potential therapeutic agents to treat canine osteosarcoma.
Mauchle U; Selvarajah GT; Mol JA; Kirpensteijn J; Verheije MH
Vet J; 2015 Aug; 205(2):281-7. PubMed ID: 25190293
[TBL] [Abstract][Full Text] [Related]
11. ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells.
Piao S; Ojha R; Rebecca VW; Samanta A; Ma XH; Mcafee Q; Nicastri MC; Buckley M; Brown E; Winkler JD; Gimotty PA; Amaravadi RK
Autophagy; 2017; 13(12):2056-2071. PubMed ID: 28981387
[TBL] [Abstract][Full Text] [Related]
12. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.
Hosoya K; Murahari S; Laio A; London CA; Couto CG; Kisseberth WC
Am J Vet Res; 2008 Apr; 69(4):519-26. PubMed ID: 18380584
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine potentiates the anti-cancer effect of bevacizumab on glioblastoma via the inhibition of autophagy.
Liu LQ; Wang SB; Shao YF; Shi JN; Wang W; Chen WY; Ye ZQ; Jiang JY; Fang QX; Zhang GB; Xuan ZX
Biomed Pharmacother; 2019 Oct; 118():109339. PubMed ID: 31545270
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
Kim Y; Eom JI; Jeung HK; Jang JE; Kim JS; Cheong JW; Kim YS; Min YH
Biomed Pharmacother; 2015 Jul; 73():87-96. PubMed ID: 26211587
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.
Barnard RA; Wittenburg LA; Amaravadi RK; Gustafson DL; Thorburn A; Thamm DH
Autophagy; 2014 Aug; 10(8):1415-25. PubMed ID: 24991836
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy.
Peng X; Zhang S; Jiao W; Zhong Z; Yang Y; Claret FX; Elkabets M; Wang F; Wang R; Zhong Y; Chen ZS; Kong D
J Exp Clin Cancer Res; 2021 Nov; 40(1):374. PubMed ID: 34844627
[TBL] [Abstract][Full Text] [Related]
18. Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.
Mantovani FB; Morrison JA; Mutsaers AJ
BMC Vet Res; 2016 May; 12():82. PubMed ID: 27245053
[TBL] [Abstract][Full Text] [Related]
19. A novel antitumour strategy using bidirectional autophagic vesicles accumulation via initiative induction and the terminal restraint of autophagic flux.
Wang Y; Tai X; Zhang L; Liu Y; Gao H; Chen J; Shi K; Zhang Q; Zhang Z; He Q
J Control Release; 2015 Feb; 199():17-28. PubMed ID: 25499918
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
